Idecabtagene vicleucel

Therapeutic indications

Idecabtagene vicleucel is indicated for:

Relapsed and refractory multiple myeloma

Population group: only adults (18 years old or older)

Idecabtagene vicleucel is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Idecabtagene vicleucel is contraindicated in the following cases:

Pregnancy

Pregnancy

Effects on ability to drive and use machines

Effects on ability to drive and use machines

Blood, organ, tissue and cell donation

at least one of
Blood unit collection
Organ retrieval operation
Transplantation

Active infections, inflammatory disorders

at least one of
Infectious disease
Inflammatory disorder

Prior allogeneic stem cell transplantation

Allogeneic peripheral blood stem cell transplant

Active graft-versus-host disease (GVHD)

Graft versus host disease

Unresolved serious adverse events

Complication of chemotherapy

Live vaccines

Live organism vaccines

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2024: ABECMA Dispersion for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈